Menu

Our actions

Our strategic drivers

GENeHOPE has identified four strategic drivers around which the Fund focuses its efforts:

1

Accelerating genetic research

~ai-f22a315d-dd25-44d5-bd89-6b8b222120ec_

2

Improving access to diagnosis and to treatment

3

Raising awareness
and mobilizing

GENeHOPE-Soutenir-patients-v2-3

4

Supporting patients and their loved ones

Our Calls for Projects

The GENeHOPE Fund launches each year, in collaboration with the King Baudouin Foundation, a call for projects to select the most promising genetic research initiatives.

Call for projects 2026

Results on 29 May

Call for Projects 2025

The first call for projects from GENeHOPE made it possible to fund four projects involving collaborative research.

Project 1

Childhood glaucoma and Xenopus model

Decoding a rare genetic mechanism behind severe childhood glaucoma — a disease affecting the optic nerve and potentially leading to blindness — using an original Xenopus model to better understand and ultimately treat adult glaucoma.
Elfride De Baere (Ghent University) – Jean-Michel Rozet (Institut Imagine)

Project 2

Kidney and pancreatic ciliopathies: understanding multi-organ involvement

Studying the interactions between kidney and pancreas in a rare ciliopathy caused by the NPHP3 gene, responsible for childhood kidney failure. The project combines fundamental research and preclinical trials.
Patrick Jacquemin (de Duve Institute, UCLouvain) – Amandine Viau (Institut Imagine)

Project 3

Loeys-Dietz syndrome and IPO8 mutation: toward better understanding of rare forms

Analyzing the effects of an IPO8 gene mutation in mouse models to uncover mechanisms behind the variability of symptoms in patients affected by this rare disorder of the vessels, skeleton, and immune system.
Marianna Parlato (Institut Imagine) – Aline Verstraeten (Center of Medical Genetics, Antwerp)

Project 4

RAPIDGEN: accelerating diagnosis of severe combined immunodeficiency (SCID) in newborns

Development of an ultra-rapid platform to validate new genes responsible for SCID, enabling vital treatments — such as bone marrow transplant — within the first weeks of life.
Filomeen Haerynck (Ghent University) – Jacinta Bustamante (Institut Imagine)

The Researchers